Hyperion DeFi, Inc. (HYPD)vsModerna Inc (MRNA)
HYPD
Hyperion DeFi, Inc.
$3.49
-2.79%
HEALTHCARE · Cap: $47.55M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 158963% more annual revenue ($2.23B vs $1.40M). HYPD leads profitability with a 474.9% profit margin vs -141.4%. HYPD earns a higher WallStSmart Score of 45/100 (D+).
HYPD
Hold45
out of 100
Grade: D+
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+84.3%
Fair Value
$25.68
Current Price
$3.49
$22.19 discount
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Keeps 475 of every $100 in revenue as profit
Revenue surging 1560.0% year-over-year
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -56.4% — below average capital efficiency
Negative free cash flow — burning cash
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : HYPD
The strongest argument for HYPD centers on Price/Book, Profit Margin, Revenue Growth. Profitability is solid with margins at 474.9% and operating margin at -758.0%. Revenue growth of 1560.0% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : HYPD
The primary concerns for HYPD are EPS Growth, Market Cap, Return on Equity.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
HYPD profiles as a growth stock while MRNA is a turnaround play — different risk/reward profiles.
HYPD carries more volatility with a beta of 2.50 — expect wider price swings.
HYPD is growing revenue faster at 1560.0% — sustainability is the question.
HYPD generates stronger free cash flow (-15M), providing more financial flexibility.
Bottom Line
HYPD scores higher overall (45/100 vs 21/100), backed by strong 474.9% margins and 1560.0% revenue growth. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Hyperion DeFi, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Hyperion DeFi, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. The company is headquartered in New York, New York.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?